Related Experiment Videos
Current perspectives on aromatase inhibitors in breast cancer
Purpose And Design:
One way to deprive hormone-dependent breast cancer of estrogen is to prevent its synthesis. This is achievable by inhibiting the aromatase cytochrome P-450 (P-450arom) enzyme complex responsible for the ultimate step in estrogen production. A new generation of specific and selective aromatase inhibitors is currently under investigation. The purpose of this review is to outline the preclinical test systems for screening these inhibitors, to summarize the preclinical and clinical data published to date, and to discuss the future application of these inhibitors in the management of breast cancer.
Results And Conclusion:
Disadvantages to the use of earlier inhibitors are described. In vitro and in vivo experiments that reflect the potency and selectivity of new inhibitors are highlighted. From preliminary clinical trials, these inhibitors appear to have excellent pharmacokinetic profiles and produce few side effects when administered orally. Activity against postmenopausal metastatic breast cancer has been demonstrated for the agents reviewed. They are all now in phase III testing to determine their relative efficacy in this setting. Their application in combination with both hormone therapy and chemotherapy, in premenopausal metastatic disease, and in the adjuvant setting in both premenopausal and postmenopausal women remains to be defined.
Insights
New aromatase inhibitors show promise for treating hormone-dependent breast cancer by blocking estrogen synthesis. Early trials indicate good tolerability and effectiveness in postmenopausal metastatic breast cancer patients.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Hormone-dependent breast cancer relies on estrogen for growth.
- Aromatase cytochrome P-450 (P-450arom) is crucial for estrogen synthesis.
- Inhibiting P-450arom offers a strategy to deprive tumors of estrogen.
Purpose of the Study:
- Review preclinical test systems for screening aromatase inhibitors.
- Summarize preclinical and clinical data for new aromatase inhibitors.
- Discuss future applications of these inhibitors in breast cancer management.
Main Methods:
- Evaluation of in vitro and in vivo experimental systems.
- Analysis of published preclinical and clinical trial data.
- Assessment of pharmacokinetic profiles and side effects of oral administration.
Main Results:
- New aromatase inhibitors demonstrate potency and selectivity.
- Preliminary clinical trials show favorable pharmacokinetic profiles and minimal side effects.
- Efficacy against postmenopausal metastatic breast cancer is demonstrated.
Conclusions:
- New generation aromatase inhibitors are effective and well-tolerated.
- Agents are advancing to Phase III trials for efficacy determination.
- Further research is needed to define their role in combination therapies and adjuvant settings.